Here are the 10-K annual reports from Zevra Therapeutics, Inc. (ZVRA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ZVRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZVRA filings page.
Zevra Therapeutics, Inc. (ZVRA) is a commercial-stage rare disease company focused on expanding access to treatments for underserved patient populations. The company’s lead product, MIPLYFFA (arimoclomol), became the first FDA‑approved therapy for Niemann‑Pick disease type C in September 2024 and is marketed in combination with miglustat in the United States. Zevra also runs a global expanded access program and has filed a Marketing Authorization Application in the European Union, now under EMA review.
Following approval, Zevra received and then sold a rare pediatric disease priority review voucher, generating $148.3 million of net proceeds that strengthen its balance sheet. The acquisition of Acer Therapeutics in 2023 added OLPRUVA for urea cycle disorders and the late‑stage celiprolol program for Vascular Ehlers‑Danlos syndrome, where a Phase 3 event‑driven trial (DiSCOVER) had 52 enrolled participants as of December 31, 2025. Zevra also earns royalties and potential milestones from the ADHD drug AZSTARYS and is advancing KP1077 for idiopathic hypersomnia and narcolepsy, supported by orphan designation and a Phase 2 trial that informed Phase 3 dosing plans.